The Team
Gene and cell therapy stand at the forefront of biotechnology. To advance against all diseases, humanity must embark on the challenging journey of tackling complex multi-gene diseases through a genuine commitment to Think Multigenic.
Meet the dedicated individuals bringing the future of gene and cell therapy to your lab today and join us as we work to expand the horizons of gene and cell therapy research.
Sam Glickstein
Co-Founder & Chief Executive Officer
Sam Glickstein brings a wealth of diverse experiences to the table, having held prominent positions in both biotech and agtech within various bioindustry companies. His expertise spans hydroponic farming, insect rearing, genetics, and protein biotechnology, reflecting his ongoing commitment to driving advancements in the field of biotechnology.
Dr. Thomas Reed
Co-Founder & Chief Science Officer
Dr. Thomas Reed, was a founder of Genomatix, a transformative force that evolved into the publicly traded entity Intrexon, now rebranded as Precigen. With an illustrious tenure as Chief Science Officer at Intrexon spanning over two decades, Dr. Reed's indelible impact culminated in the launch of Osprey BioScience in December 2022.
Austin Peppel
Chief Technology Officer
Austin Peppel brings years of valuable experience to project engagements, encompassing software and firmware engineering, visual effects, digital fabrication, and the establishment and implementation of operational design standards.
Lilith Saylor
Marketing & Analytics
Lilith Saylor, with 4 years of analytics experience and a passion for all things data, brings much to the Osprey team. Transitioning seamlessly from political campaigns to academia and now making her mark in the biotech industry, Lilith brings a versatile skill set to promote compelling ideas and decipher their market performance.
OspreyBio Board
We are privileged to have the following distinguished individuals working with us as OpreyBio's board. The wealth of experience they bring is difficult to match in the field of biotools, entrepreneurship, and business development. Together, our board members form a synergistic team, combining their diverse skills and knowledge to guide our company in becoming a leader in the biotools industry. Their commitment to excellence and innovation is not only inspiring but also a driving force behind our success.
Dr. Aris Persidis
Dr. Persidis is President and co-founder of Biovista. He has also served as Senior Vice President at Upstate/Serologicals, Managing Director and President of RHeoGene, and Assistant Director-Medical School Technology Transfer Program – and Assistant Professor (Adjunct) at the Entrepreneurial Center of the Wharton School of Business at the University of Pennsylvania (1993-1997). Dr. Persidis is also a co-founder of Cellzome, in Heidelberg, Germany, and participated in the founding of Anadys, San Diego, CA. Dr. Persidis holds a First Class B.Sc. Degree in biological chemistry from Essex University, U.K. (1983-1986), and a Ph.D. in biochemistry from the University of Cambridge, U.K. (1986-1989).
Dr. J. Mark Braughler
Dr. Braughler has had more than 30 years in the medical, pharmaceutical and biotechnology industries. His last position was senior vice president of clinical development and regulatory affairs at Intrexon (now Precigen, PGEN). At Intrexon, Dr. Braughler oversaw all activities related to its cancer immunotherapy clinical trials and FDA interactions. Prior to Intrexon, he was CEO of Argonex/Upstate Biotechnology. Earlier in his career, Dr. Braughler served as vice president of business development for Pharmacia & Upjohn, where he oversaw all licensing, merger, and acquisition activity worldwide.
Karen Padgett
Karen Padgett, a highly accomplished senior executive with over 25 years of success in the biotech and life sciences industry, has consistently demonstrated a proven ability to challenge the status quo and develop strategic plans that drive organizational growth. Serving as the founder and CEO of Novus Biologicals, she led the company to $23 million in revenues and orchestrated the successful acquisition of the business between 1996 and 2014. Following this achievement, Karen took on the role of Vice President of Global Marketing at Bio-Techne from 2016 to 2018. In addition to her significant leadership roles, Karen has continued to contribute to the industry through her consulting, advising, and investment activities. As a board member for Janel, CellIDX, eMolecules, she leverages her expertise to guide strategic decisions and foster growth in diverse organizations.
